Previous 10 | Next 10 |
2023-07-11 11:18:16 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were down more than 8% as of 10:45 a.m. ET on Tuesday after the biotech announced a public stock offering. The stock is up more than 26% so far this year. Iovance specializes in tumor infiltrating lympho...
2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...
2023-07-11 09:26:40 ET The Nasdaq Composite (NASDAQINDEX: ^IXIC) has performed extraordinarily well in 2023, getting off to its best first half of a year since the 1980s. Even though it has already recovered a lot of its lost ground from 2022's bear market, the Nasdaq has held up we...
2023-07-11 06:41:21 ET Summary Rite Aid's shares fell amid reports that the company is considering a Chapter 11 filing to address liabilities related to its opioid exposure; a bankruptcy filing is not confirmed or imminent. Berkshire Hathaway Energy is set to buy Dominion Energy's...
2023-07-11 05:44:50 ET The New Era For Commercial Banking Recession Risk - Expecting The Unexpected Jobs And Earning Data Support Continued Hot Economy For further details see: Biggest stock movers today: Iovance Biotherapeutics and Viridian Therapeutics
2023-07-11 01:30:52 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) on Monday announced pricing of an underwritten public offering of 20 million shares of its common stock at a $7.50 per share. The stock is down about 10% to $7.92 after-hours on Monday...
2023-07-10 18:11:11 ET Summary Iovance Biotherapeutics, Inc. had a positive Type B Pre-Phase 3 meeting with the FDA, whereby IOV-LUN-202 trial will be allowed for Accelerated Approval of LN-145 for the treatment of NSCLC patients. Positive preliminary results achieved in registrat...
2023-07-10 17:03:22 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) on Monday announced a proposed stock offering of up to $150M. Shares of IOVA fell 9% to $8 after hours. "All of the shares in the offering are to be sold by Iovance ( IOVA )," the company said in a s...
2023-07-10 07:25:23 ET Citing FDA feedback, Iovance Biotherapeutics ( NASDAQ: IOVA ) announced Monday that the design for the company’s ongoing IOV-LUN-202 trial for the lung cancer candidate LN-145 could be acceptable for a potential accelerated approval. The FDA indicat...
Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Registrational IOV-LUN-...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, In...
2024-06-28 04:05:00 ET Earlier this year, share prices of Iovance Biotherapeutics (NASDAQ: IOVA) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less...
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...